CancerCancer.org - The Social Support Network for People Living with Cancer

US cancer care: Treatment choices are all about you

WASHINGTON (AFP) — US cancer experts are preparing to focus on new
developments in making treatment ever more personalized, right down to
the molecular level, at their main annual gathering this weekend.

"We
have a theme at the meeting this year: personalizing cancer care,
ranging from using molecular analysis to select the most appropriate
treatment for patients through developing personalized survivalship
care plans for cancer survivors," said Richard Schilsky, president of
the American Society of Clinical Oncology (ASCO), which is holding its
annual meeting in Orlando, Florida.

Worldwide, about 13 percent
of deaths are caused by cancer. Results from dozens of clinical studies
will be released at the gathering opening Friday and running through
June 2. Some 30,000 people are expected to take part.

"I think
it's clear to all of us who are treating cancer patients that oncology
is no longer one-sided; it's all medicine," Schilsky said, noting that
great strides had been made in selecting the best treatments for a
given patient.

"We are increasingly able to tailor treatment to
an individual," such as their particular tumor biology, "matching the
right treatment to the right patient at the right time allowing
patients to avoid unnecessary cost and side effects from therapy that
won't help them," Schilsky stressed. "It's very clear to me that is the
future of cancer medicine."

In total, 4,000 research works were
accepted by ASCO on a broad range of topics in oncology, said Eric
Winer, a Harvard University professor associated with the group.

Seven
press conferences have been scheduled, including two on Saturday on the
results of gastrointestinal tumors and advanced lung cancer research.

Two
more are planned for Sunday to discuss results of breast cancer and
ovarian cancer research, as well as personalized treatment plans.

On Monday, experts will discuss strides made in cancer care, as well as on current major challenges facing oncology.

Among
the clinical results due out are phase two trial results on Nexavar,
made by Germany's Bayer for advanced lung cancer treatment.

Nexavar,
which works by blocking the growth of blood vessels feeding a tumor,
leading to the death of some cancer cells, already is marketed in more
than 70 countries as a liver cancer treatment.

Results are also
awaited with interest on Avastin, a breast cancer treatment by US firm
Genentech, which has been bought by Switzerland's Roche.

Cancer
is a leading cause of death in the world, blamed for 7.4 million deaths
in 2004, according to the World Health Organization (WHO). The
deadliest cancers are lung, stomach, colon, liver and breast cancer.

About 30 percent of cancer deaths could be avoided, the WHO says, with smoking the leading lifestyle risk.

Cancer
begins with the modification of a single cell -- and can be caused by
external, genetic or hereditary factors, or a combination of these.

LINK: http://www.google.com/hostednews/afp/article/ALeqM5jtr7Bh7vbWGqwo2HvwcteaYWeqgw